Evidence map›Paper›PMID 41903007›Full record

ReviewDiscover oncology2026

Advances and challenges of sonodynamic nanomedicines for deep seated tumor therapy.

Jinlong Zhao, Yongxiang Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jinlong ZhaoState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, 530021, Guangxi, China. jinlongzhao@sr.gxmu.edu.cn.
Yongxiang ZhaoState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, 530021, Guangxi, China. zhaoyongxiang@gxmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sonodynamic therapy (SDT) has become a promising, noninvasive treatment modality with deep tissue penetration and precise controllability, offering a new approach for cancer treatment. Nanotechnology improves stability, targeting ability, and therapeutic efficiency of sonosensitizers in deep-seated tumors. This review discusses recent advances in sonodynamic nanomedicines for treating pancreatic, hepatic, and colorectal cancers, focusing on design strategies and mechanisms of metal-based, nonmetal-based, and hybrid nanosystems. Current challenges such as limited reactive oxygen species (ROS) generation, insufficient tumor targeting, hypoxia tolerance, and biosafety concerns are discussed. Future perspectives on multimodal combination therapy, stimuli-responsive nanocarriers, and clinical translation are also highlighted. This review aims to provide insights into the rational design and clinical development of SDT-based nanomedicines for deep-seated tumors.

Indexed as

Deep-seated tumorNanomedicineReactive oxygen speciesSonodynamic therapyTumor microenvironment

Identifiers

PMID41903007
PMCPMC13149719

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.